An iron soap having a content A (%) of free fatty acid being 0.01≦A≦8.0, a content B (%) of water soluble salt being 0.01≦B≦0.5, and a granularity summary value C indicated in Formula (1) being 0.1≦C≦5.0, wherein the iron soap is a salt of a straight-chain saturated fatty acid having from 12 to 22 carbons and an iron.

Granularity summary value C=(D90−D10)/D50(where 1.0≦D50≦40.0)  Formula (1)

D10: 10% cumulative diameter (μm) of fatty acid metal salt particles on a volumetric basis

D50: 50% cumulative diameter (μm) of fatty acid metal salt particles on a volumetric basis

D90: 90% cumulative diameter (μm) of fatty acid metal salt particles on a volumetric basis

A rubber-metal adhesion promoter characterized by including a compound (1) represented by the following general formula (A): (in the formula, Z represents a structure selected from the following formulae (z-1) to (z-4); M represents titanium or zirconium; and (RCOO) represents a residue of an aliphatic carboxylic acid having 2 to 25 carbon atoms)

##STR00001##

A rubber-metal adhesion promoter characterized by including a compound (1) represented by the following general formula (A): (in the formula, Z represents a structure selected from the following formulae (z-1) to (z-4); M represents titanium or zirconium; and (RCOO) represents a residue of an aliphatic carboxylic acid having 2 to 25 carbon atoms)

##STR00001##

A rubber-metal adhesion promoter characterized by including: a metal salt (1) of a carboxylic acid which is a metal salt of an aliphatic carboxylic acid having 2 to 25 carbon atoms and in which the metal is bismuth, copper, antimony, silver or niobium; or a compound (2) represented by the following general formula (A): [wherein Z represents a structure selected from the following formulae (z-1) to (z-4); M represents bismuth, copper, antimony, silver or niobium; (RCOO) represents a residue of an aliphatic carboxylic acid having 2 to 25 carbon atoms; and x represents the valence of M minus 1].

##STR00001##

A rubber-metal adhesion promoter characterized by including: a metal salt (1) of a carboxylic acid which is a metal salt of an aliphatic carboxylic acid having 2 to 25 carbon atoms and in which the metal is bismuth, copper, antimony, silver or niobium; or a compound (2) represented by the following general formula (A): [wherein Z represents a structure selected from the following formulae (z-1) to (z-4); M represents bismuth, copper, antimony, silver or niobium; (RCOO) represents a residue of an aliphatic carboxylic acid having 2 to 25 carbon atoms; and x represents the valence of M minus 1].

##STR00001##

The present disclosure relates to a ligand for a quantum dot, a ligand quantum dot, a quantum dot layer and a method for patterning the same. The surface of the ligand quantum dot of the present disclosure is connected with the cleavage-type ligand including a first ligand unit A, a cleavage unit B, and an adhesion adjusting unit C. The method includes: providing a substrate; coating a mixture containing the ligand quantum dot on the substrate to form a quantum dot film; exposing a preset region of the quantum dot film to ultraviolet light, so that the cleavage unit B in the cleavage-type ligand undergoes a photolysis reaction, and a molecular segment containing the adhesion adjusting unit C and obtained after decomposition is detached from a surface of the quantum dot; and washing off an unexposed region of the quantum dot film with an organic solvent, followed by drying.

A multicomponent crystal (or co-crystal) comprising a first active pharmaceutical ingredient and a second active pharmaceutical ingredient. The multicomponent crystal is formed/sustained by non-covalent interactions between the nitrogen-containing heterocycle alpha-substituted with an amino group of the first active pharmaceutical ingredient and a carboxylic acid group of the second active pharmaceutical ingredient, suitably as well as other further non-covalent interactions with other H-bond forming groups. The multicomponent crystal may provide an improved multidrug dosage form comprising lamotrigine and valproic acid as the first and second active pharmaceutical ingredients, respectively. A pharmaceutical composition comprising a therapeutically effective amount of the multicomponent crystal and a pharmaceutically acceptable excipient, and a method of forming the multicomponent crystal, are also provided.

A method of manufacturing an iron soap is disclosed herein. The method comprising the steps of: reacting, at a temperature equal to or lower than a crystal transition initiation temperature of the iron soap to be manufactured, between a straight-chain saturated fatty acid alkali metal salt aqueous solution having from 12 to 22 carbons and a trivalent iron salt aqueous solution with pH of 0.1 to 5.5 so as to prepare an iron soap slurry; and adjusting pH of the prepared iron soap slurry to from 0.1 to 6.0.

A method of manufacturing an iron soap is disclosed herein. The method comprising the steps of: reacting, at a temperature equal to or lower than a crystal transition initiation temperature of the iron soap to be manufactured, between a straight-chain saturated fatty acid alkali metal salt aqueous solution having from 12 to 22 carbons and a trivalent iron salt aqueous solution with pH of 0.1 to 5.5 so as to prepare an iron soap slurry; and adjusting pH of the prepared iron soap slurry to from 0.1 to 6.0.

A method of manufacturing an iron soap is disclosed herein. The method comprising the steps of: reacting, at a temperature equal to or lower than a crystal transition initiation temperature of the iron soap to be manufactured, between a straight-chain saturated fatty acid alkali metal salt aqueous solution having from 12 to 22 carbons and a trivalent iron salt aqueous solution with pH of 0.1 to 5.5 so as to prepare an iron soap slurry; and adjusting pH of the prepared iron soap slurry to from 0.1 to 6.0.